John P. Furey
John P. Furey
Chief Executive Officer

As Chief Executive Officer, John P. Furey leads the company’s development of its novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers. He also serves on the Imvax Board.

Most recently, John was Chief Operating Officer of Spark Therapeutics, Inc., where he led the successful US launch of LUXTURNA™, the first FDA-approved gene therapy for a genetic disease, and contributed to the build out of Spark as a fully integrated company. Prior to Spark, Mr. Furey served as Senior Vice President and Head of Global Operations at Baxalta, where he transformed the company’s global operations into a first-in-class supply chain network for rare diseases and led the 14,000-employee manufacturing, quality, engineering and process development organization. Earlier in his career, Mr. Furey initiated the restructuring and ultimate divestiture of Baxter International’s vaccines franchise to Pfizer. While at Pfizer, he transformed the China vaccine business into one of the company’s fastest growing units.

Mr. Furey also currently serves as non-executive director at Adaptimmune, a leader in T-cell therapy, and is an indepdent board member of Sensorion, a pioneering clinical-stage biopharmaceutical company developing therapies for the ear.

Mr. Furey earned an Executive MBA (Pharmaceutical Marketing) from St Joseph’s University, in Philadelphia, a Bachelor of Science with Honors from Trinity College, Dublin, and a Diploma in Environmental Health from the Dublin Institute of Technology.

David W. Andrews, MD
David W. Andrews, MD
Co-Founder, Chief Medical Officer

As Chief Medical Officer at Imvax, Inc., Dr. Andrews communicates and engages with clinicians, researchers, and other key opinion leaders in the field regarding clinical development activities and potential product development. He develops strategic plans for the company’s product portfolio to ensure that development programs meet quality and safety standards required by patients, health care providers, and regulatory agencies. Dr. Andrews has a 30-year experience as an academic brain tumor neurosurgeon, completing residency at New York Presbyterian Cornell and a Fellowship at Memorial Sloan Kettering Cancer Center, both in New York, NY. As a junior attending neurosurgeon, he received a prestigious NIH Physician Scientist Award to study brain tumors and has devoted his career to find better treatment for glioblastoma. He currently resides at Thomas Jefferson University Hospital where he is Professor and Vice Chair of Clinical Services, Department of Neurological Surgery, and Chief of the Division of Neuro-Oncology.

Dr. Andrew’s raised nearly $7M dollars in philanthropy over a 20-year period to advance this promising immunotherapy platform for GBM, collaborating closely with his colleague Dr. Craig Hooper, a talented neuro-immunologist. He established the Brain Tumor Division at Thomas Jefferson University Hospital in 1995 and served as its Chief, expanding the Division to four neurosurgeons and two neuro-oncologists before stepping down to assume his role as a founder of Imvax, Inc. in 2015. Under his leadership, the Division became a national leader performing over 1,100 brain tumor treatments a year. His vision with Imvax, Inc. is to accelerate the development of this promising vaccine treatment.

Mark Exley, PhD
Mark Exley, PhD
Chief Scientific Officer

Mark Exley, PhD, is Imvax’s Chief Scientific Officer (CSO). Dr. Exley was previously Vice President, Cellular Immunology for AgenTus.

Dr. Exley’s areas of research have included natural and vaccine-supported immunity to cancers, immune responses to acute and chronic viral infections, suppression of graft-versus-host disease (a serious complication of bone marrow and stem cell transplants), obesity-associated diseases and other inflammations. Dr. Exley has published over 120 articles in scientific journals and has received numerous research awards and grants.

Prior to joining Imvax, Dr. Exley was on faculty at Harvard Medical School and at the University of Manchester, UK, where he retains honorary appointments, and was a scientist at Immulogic, Inc. He received his BS from Imperial College, London and his Ph.D. from the Institute of Cancer Research, London. He completed his post-doctoral fellowship at the Dana Farber Cancer Institute.

Sean Hemingway, MS
Sean Hemingway, MS
Chief Operating Officer

With over twenty-five years of experience in the life sciences industry, Sean Hemingway has progressed through roles in project management, product operations, strategy, and operations. He has held various executive positions, beginning with positions in engineering, tech transfer, project and program management and moving into executive roles in corporate operations, product, and strategy management. Sean’s professional experience includes roles at Pfizer, Genzyme, and Baxalta, and he most recently was the Global Head of the BioLife Plasma Services business unit at Takeda. In addition, Sean has worked in domestic and international positions and has played key roles in several corporate integrations.

He holds a B.S. in Chemical Engineering from the University of Rhode Island and an M.S. in Engineering Management from Tufts University.

Catherine Kessler, MS
Catherine Kessler, MS
Chief Regulatory Officer

As Chief Regulatory Officer at Imvax, Inc., Catherine Kessler is responsible for oversight and management of regulatory affairs including nonclinical, clinical and CMC regulatory strategies and compliance within the company. Catherine has over 25 years of experience in the biotechnology and pharmaceutical industry, and has been working in regulatory affairs, quality assurance, regulatory compliance and operations activities since 2001. She has supported early and late-stage drug development in multiple therapeutic areas including oncology, inflammatory and cardiovascular diseases, and contraception and women’s health.

Ms. Kessler’s experience and knowledge of human blood therapeutics, biologics, and small molecules was gained while working in companies including Clinipace Clinical Research, Array BioPharma, Amgen, Aventis Behring, Centocor, and SmithKline Beecham Pharmaceuticals. She is well-versed in regulatory research and surveillance, developing regulatory paths to market for unique and complex investigational products, and engaging health authorities through the complex stages of clinical development. Ms. Kessler holds a BS in Biochemistry from the University of Delaware in Newark, DE and an MS in Quality Assurance and Regulatory Affairs from Temple University in Ambler, PA.

John M. Limongelli
John M. Limongelli
Chief Legal Officer

John M. Limongelli previously served as senior vice president, general counsel and corporate secretary at Neos Therapeutics, Inc., a publicly traded biotechnology company, and senior vice president, general counsel and chief administrative officer at Trevena, Inc. (NASDAQ: TRVN). He also has held high-level level legal roles at Cigna Corporation as corporate secretary, Adolor Corporation, a publicly traded biotechnology company, as senior vice president, general counsel and secretary, and Cephalon, Inc., a publicly traded biotechnology company, as vice president and associate general counsel. John began his legal career in private practice with Morgan, Lewis & Bockius, LLP, and was a certified public accountant with KPMG LLP. He obtained both his J.D. and MBA from Temple University.

Josh Muntner, MBA
Josh Muntner, MBA
Chief Financial Officer

Josh Muntner most recently served as chief financial officer at Mesoblast Limited, a late-stage biotechnology company. He has more than twenty years of experience in healthcare investment banking and corporate finance, providing strong expertise in areas of capital markets and fundraising. Josh has also played a lead role in a wide range of healthcare-related transactions. Earlier in his career, he held the position of senior vice president of business development at biotechnology company ContraFect Corporation and served as managing director and co-head of healthcare investment banking at Janney Montgomery Scott. Prior, Josh worked at Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets. He holds a bachelor’s degree from Carnegie Mellon University and an MBA from the Anderson School of Management at the University of California, Los Angeles.